{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:37:41Z","timestamp":1787510261679,"version":"build-2736575974"},"reference-count":97,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T00:00:00Z","timestamp":1364947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>\n                    Four breakpoint cluster region (\n                    <jats:styled-content style=\"fixed-case\">BCR)<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content>\n                    1 tyrosine kinase inhibitors (\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    s) are currently available for the treatment of chronic myeloid leukemia (\n                    <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\n                    ): imatinib, nilotinib, dasatinib, and bosutinib. Choosing the most appropriate\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    requires clinicians to consider a host of patient\u2010, disease\u2010, and treatment\u2010related factors, not the least of which include the safety profiles of the agents. This review discusses the potential impact of treatment\u2010, patient\u2010, and disease\u2010related characteristics on the emergence of adverse events during\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    therapy, with a focus on the underlying mechanisms believed to be responsible for a number of important adverse events associated with these agents and what implications they may have for treatment choice, particularly in the setting of first\u2010line treatment. A literature search of the\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    ub\n                    <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>\n                    ed database was conducted to identify articles that described the molecular mechanisms of\n                    <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content>\n                    1\u2013mediated leukemic transformation, the efficacy and safety of imatinib, nilotinib, dasatinib, and bosutinib in patients with\n                    <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\n                    , the kinase\u2010binding spectrum of each\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    , and evidence suggesting a link between the\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    \u2010binding profile and adverse events. The pattern of adverse events associated with each agent is important when selecting treatment with a\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    . Clinical studies suggest that imatinib, nilotinib, dasatinib, and bosutinib have differing safety profiles, which are in part attributable to the specificity and selectivity of each agent. Although much basic research must be conducted to further illuminate the mechanisms responsible for\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    \u2010related adverse events, on\u2010 and off\u2010target effects are believed to be at least partly responsible for cardiovascular toxicity, myelosuppression, fluid retention, gastrointestinal toxicity, and dermatologic toxicity. Increased understanding of the factors that affect\n                    <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>\n                    \u2010associated adverse events and long\u2010term safety data will enable a more informed approach to the selection of therapy best suited to the individual needs of patients with\n                    <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1002\/phar.1266","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T09:49:40Z","timestamp":1364982580000},"page":"868-881","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment\u2010, Patient\u2010, and Disease\u2010Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia"],"prefix":"10.1002","volume":"33","author":[{"given":"Elizabeth","family":"Irvine","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Kansas Hospital Kansas City Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Williams","sequence":"additional","affiliation":[{"name":"Sanford Research\/USD Edith Sanford Breast Cancer Initiative Sioux Falls South Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,3]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/315758a0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480901600202"},{"key":"e_1_2_9_6_1","first-page":"100","article-title":"Inhibition of the Abl protein\u2010tyrosine kinase in vitro and in vivo by a 2\u2010phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077958"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801896103"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein\u2010tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c\u2010kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdunger E","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.11.008"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_9_13_1","first-page":"375","article-title":"SKI\u2010606, a 4\u2010anilino\u20103\u2010quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas JM","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.334"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib (abstract)","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_9_18_1","volume-title":"Bosulif (bosutinib) prescribing information","author":"Pfizer Labs","year":"2012"},{"key":"e_1_2_9_19_1","volume-title":"Sprycel (dasatinib) prescribing information","author":"Bristol\u2010Myers Squibb Company","year":"2011"},{"key":"e_1_2_9_20_1","volume-title":"Tasigna (nilotinib) prescribing information","author":"Novartis Pharmaceuticals Corporation","year":"2012"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603170"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8853"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_2_9_30_1","first-page":"159b","article-title":"BMS\u2010354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad\u2010spectrum antitumor activities in vitro and in vivo","volume":"46","author":"Lee FY","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/jco.2012.30.15_suppl.6504","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): DASISION 3\u2010year follow\u2010up (abstract)","volume":"30","author":"Hochhaus A","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029828"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.03.018"},{"key":"e_1_2_9_41_1","volume-title":"Gleevec (imatinib mesylate) prescribing information","author":"Novartis Pharmaceuticals Corporation","year":"2012"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1458-6"},{"key":"e_1_2_9_43_1","volume-title":"Tarceva (erlotinib) prescribing information","author":"Genentech Inc","year":"2012"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.057"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0107-13a"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210378913"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial (abstract)","volume":"116","author":"Saglio G","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3869"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.03.001"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10239"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.01.017"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13068"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_9_57_1","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood.V118.21.2757.2757","article-title":"Retrospective cohort analysis of peripheral arterial occlusive disease (PAOD) events in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) (abstract)","volume":"118","author":"Giles FJ","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_58_1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.V118.21.2753.2753","article-title":"Nilotinib exerts direct effects on vascular endothelial cells and may act as a co\u2010trigger of atherosclerosis in patients with Ph+ CML (abstract)","volume":"118","author":"Hadzijusufovic E","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr292"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22051"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005"},{"key":"e_1_2_9_62_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 4.2013. Available fromhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed March 1 2013."},{"key":"e_1_2_9_63_1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood.V118.21.3768.3768","article-title":"Nilotinib shows safety and efficacy in older patients (>= 65\u00a0years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd (abstract)","volume":"118","author":"Larson RA","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.323"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.627480"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"e_1_2_9_67_1","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2012.30.15_suppl.6506","article-title":"Six\u2010year (yr) follow\u2010up of patients (pts) with imatinib\u2010resistant or \u2010intolerant chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) receiving dasatinib","volume":"30","author":"Shah NP","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00154210"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-11-30"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.08.007"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"e_1_2_9_75_1","unstructured":"US Food and Drug Administration.FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension. Available fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm275155.htm. Accessed June 22 2012."},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.05.015"},{"key":"e_1_2_9_77_1","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood.V116.21.3421.3421","article-title":"Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML\u2010CP): analysis of the DASISION Trial (abstract)","volume":"116","author":"Khoury HJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v2.i2.80"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.111"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02122.x"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(06)97011-0"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2106"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2009.12.032"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63716-9"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(99)00078-3"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.5.1710"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0069"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605366"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/42.11.7523489"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00272.x"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0003"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404827"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.4.297"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318949"},{"key":"e_1_2_9_98_1","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML\u2010CP) intolerant to imatinib: a retrospective analysis of safety (abstract)","volume":"26","author":"Khoury HJ","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1266","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:33:08Z","timestamp":1761067988000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,3]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/phar.1266"],"URL":"https:\/\/doi.org\/10.1002\/phar.1266","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,3]]},"assertion":[{"value":"2013-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}